| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9892225 | The Journal of Steroid Biochemistry and Molecular Biology | 2005 | 6 Pages |
Abstract
Recent evidence demonstrates that growth factor networks are highly interactive with the estrogen receptor (ER) in the control of breast cancer growth and development. As such, tumor responses to anti-hormones are likely to be a composite of the ER and growth factor inhibitory activity of these agents, with alterations/aberrations in growth factor signalling providing a mechanism for the development of anti-hormone resistance. In this light, the current article focuses on illustrating the relationship between growth factor signalling and anti-hormone failure in our in-house tumor models of breast cancer and describes how we are now beginning to successfully target their actions to improve the effects of anti-hormonal drugs and to block aggressive disease progression.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
R.I. Nicholson, I.R. Hutcheson, D. Britton, J.M. Knowlden, H.E. Jones, M.E. Harper, S.E. Hiscox, D. Barrow, J.M.W. Gee,